

**REMARKS**

Claims 1-4, 20-22, 30-33, 50, and 51 are pending in this application. No amendments have been made.

**Restriction Requirement**

The Office Action states that there are multiple inventions in the application and requests restriction to one of the following groups (Applicants' representative has corrected what were perceived to be obvious errors in the groups):

- I. Claims 1-4 drawn to a method of detecting cancer related marker protein;
- II. Claims 20-22, and 50, drawn to diagnostic reagents;
- III. Claims 30-33, 50, and 51, drawn to cell lines capable of producing autoantibodies against breast cancers;
- IV. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with lymphomas;
- V. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with leukemias;
- VI. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with colorectal cancers;
- [VI]VII. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with lung cancer;
- VIII. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with pancreatic cancers;
- IX. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with prostate cancers;
- [X. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with lymphomas]

- X. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with cervical cancers;
- XI. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with ovarian cancer;
- XII. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with endometrial cancers;
- XIII. Claims 30-32, 50, 51 drawn to cell lines capable of producing autoantibodies against an epitope of marker protein associated with skin cancers.

Applicants hereby elect Group I, Claims 1-4 drawn to a method of detecting cancer related marker protein, with traverse.

**Election of Species**

The Office Action further requires an election of species. The species are as follows:

- a) MUC1
- b) BRCA1
- c) BRCA2
- d) p53
- e) c-myc
- f) c-erb-beta2
- g) Ras

Applicants hereby elect a) Muc 1.

Applicants understand that these are provisional election of species and that if no prior art is found which anticipates or renders obvious the elected species, the

search of the generic claims will be extended to the extent necessary to determine patentability of the generic claims.

Applicants respectfully submit that this is a complete response to the Election/Restriction Requirement dated February 26, 2003. Early and favorable consideration is earnestly solicited. If the Examiner believes there are other issues that can be resolved by telephone interview, or that there are any informalities remaining in the application which may be corrected by Examiner's Amendment, a telephone call to the undersigned attorney at (404) 815-6500 is respectfully solicited.

Respectfully submitted,



By: Janina A. Malone  
Reg. No. 47,768

KILPATRICK STOCKTON, LLP  
1100 Peachtree Street  
Suite 2800  
Atlanta, GA 30309-4530  
Phone: (404) 815-6500  
Fax: (404) 815-6555  
Atty Docket: 02332-0020 (49409/264826)